Practice
Peter Lyons, widely recognized as one of the most prominent M&A lawyers in the United States, represents leading U.S. and global companies in acquisitions and sales of public and private companies, asset acquisition and disposition transactions, and joint ventures.

Mr. Lyons has been recognized and recommended as an M&A practitioner by Chambers Global, Chambers USA, Legal 500 US, IFLR1000 and PLC Which Lawyer?.

Mr. Lyons has written and spoken extensively on M&A and corporate law. He joined the firm in 1980 and became a partner in 1989.

• Gambro AG in the sale of the issued and outstanding stock of CaridianBCT Holding Corp. to Terumo Corporation; Gambro AB in its acquisitions of Cobe Laboratories, Inc. and Vivra Incorporated; its investments in, and subsequent acquisition of, Ren-Corporation USA; its investment in Hemasure, Inc.; its divestiture of Gambro Healthcare, Inc. to DaVita Inc.; its distribution agreement with Baxter Healthcare Corporation; and its independent directors in the acquisition of Gambro by Indap AB
• Sterling Bancshares, Inc. in its acquisition by Comerica Incorporated
• Sun Pharmaceutical Industries in its acquisition of Caraco Pharmaceutical Laboratories, Ltd. and Tara Pharmaceutical Industries Ltd.
• The independent directors of Psychiatric Solutions, Inc. in its acquisition by Universal Health Services, Inc.
• Shiseido Company, Ltd. in its acquisition of Bare Escentuals, Inc.
• Data Domain, Inc. in its acquisition by EMC Corporation
• Dakota, Minnesota & Eastern Railroad Corporation in its acquisition by Canadian Pacific Railway Limited
• Nokia Corporation in the formation of Nokia Siemens Networks and the acquisition of Navteq Corporation
• IntercontinentalExchange, Inc. in its acquisition of The Clearing Corporation; the formation of ICE US Trust; and the establishment of the leading clearing house for credit default swaps
• BiogenIdec in its 2008 proxy contest with Carl Icahn
• Siemens AG and its subsidiaries in the sale of its worldwide pacemaker business to St. Jude Medical and Unisphere, Inc. to Juniper Networks, Inc.; and the acquisitions of UGS Corporation, Efficient Networks, Pyramid Technologies, Sylvania's North American lighting business from GTE; and the water systems and services division of United States Filter Corporation, a subsidiary of Veolia Environment S.A.
• JetBlue Airways Corporation in the sale of 19% of its common stock to Deutsche Lufthansa AG
• Boston Scientific Corporation in its acquisitions of Guidant Corporation, Scimed Life Systems, Inc., Cardiovascular Imaging Services, Inc., Meadox Medicals, Inc., Mintec, Inc., the Schneider division of Pfizer Inc., Target Therapeutics, Inc., Interventional Technologies Inc. and Quanam Medical Corporation; the sale of Guidant's vascular intervention business to Abbott Laboratories; and its equity investment in Biophan Technologies, Inc.
• Mitel Networks Corporation in its acquisition of Inter-Tel (Delaware) Incorporated
• BASF AG in its acquisitions of Engelhard, Micro Flo Co., Chemdal, Cyanamid Corporation and the Latex Division of Polysar Limited; the swap of its container coatings business for the surfactants business of PPG Industries; the swap of its fibers business for Honeywell, Inc.'s plastics business; and the sale of its Fritzsche Dodge & Cie flavors and fragrance business

• Member of the Board of Editors of The M&A Lawyer
• Member of Faculty of Tulane Corporate Law Institute, 2000-present

Conferences

• Participated in the Securities and Exchange Commission’s Roundtable on Implementation of Internal Control Reporting Provisions